Human SLC1A2 Protein, Flag,His Tag (Detergent)

ユーザーレビュー
製品番号/仕様
価格
数量
SL2-H52D6-20ug
$805.00
SL2-H52D6-100ug
$2985.00
SL2-H52D6-500ug
$7480.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Application

    1. Immunization
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    DEE41, EAAT2, EIEE41, GLT-1, GLT1, HBGT

  • Source

    Detergent Human SLC1A2 Protein, Flag,His Tag (SL2-H52D6) is expressed from human 293 cells (HEK293). It contains AA Ala 2 - Lys 574 (Accession # P43004).

    Predicted N-terminus: Met

    Request for sequence
  • Molecular Characterization

    SLC1A2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a flag tag at the N-terminus and a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 66.0 kDa. The protein migrates as 55-70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    *The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Each full-length transmembrane protein is encapsulated by detergent micelle.

    2. Synthesis Process

      Through mild detergent micelle extraction, dedicated solubilization, and stringent affinity purification, we maximally retain the native transmembrane conformation of full-length transmembrane proteins throughout downstream purification. This workflow yields purified, detergent-solubilized proteins free of unrelated membrane impurities and exogenous scaffold proteins, with exceptional purity, accurate quantitation, and well-preserved biological activity—ideal for immunization, binding assays in antibody discovery and screening (ELISA) and affinity testing (SPR and BLI), etc.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    This product is not suitable for cell based experiments due to cytotoxicity of DDM.
    DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
    DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
    If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    SLC1A2 SDS-PAGE

    Human SLC1A2 Protein, Flag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     SLC1A2 ELISA

    Immobilized Human SLC1A2 Protein, Flag,His Tag (Cat. No. SL2-H52D6) at 10 μg/mL (100 μL/well) can bind Monoclonal Anti-Human SLC1A2 antibody, Mouse IgG with a linear range of 0.002-1.25 μg/mL (QC tested).

    Protocol

ユーザーレビュー
コメントを投稿

  • E***a2026-04-29
    いいね
    We used this a POC and it worked in some assays where we got informative data. It is great to see detergent-stabilized proteins becoming more available commercially.

バックグランド

SLC1A2 encodes EAAT2 (GLT-1), the predominant astrocytic glutamate transporter responsible for clearing over 90% of synaptic glutamate in the central nervous system. This prevents excitotoxic neuronal injury. Impaired EAAT2 function is heavily implicated in amyotrophic lateral sclerosis (ALS), epilepsy, and ischemic stroke, making it a compelling target for neuroprotective therapeutic strategies.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Excitatory amino acid transporter 2

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    2 詳細

  • 最新の開発ステージ:

    Phase 2 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8